Want to see GB:CNSL full AI Analyst Report?
CNSL Stock Chart & Stats
1.85 p
-0.06 p(-3.71%)
At close: 4:00 PM EDT
1.85 p
-0.06 p(-3.71%)
Day’s Range― - ―
52-Week Range1.26 p - 2.80 p
Previous CloseN/A
Volume526.81K
Average Volume (3M)560.26K
Market Cap
£4.05M
Enterprise Value1.89M
Total Cash (Recent Filing)£2.64M
Total Debt (Recent Filing)£125.00K
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Nov 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding237,950,650
10 Day Avg. Volume391,637
30 Day Avg. Volume560,263
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.77
Price to Sales (P/S)0.63
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage limits balance-sheet risk and reduces the burden of interest and refinancing obligations. This gives Omega greater flexibility to fund operations, absorb earnings volatility, and pursue investment without relying heavily on additional borrowing.
Resilient Gross MarginsThe company has maintained a solid gross-margin structure despite volatile revenue and earnings. This indicates that its diagnostic products can retain meaningful gross profit before operating costs, providing a foundation for recovery if sales stabilize and expenses are controlled.
Broad IVD Product OfferingOmega participates across multiple parts of the in-vitro diagnostics value chain, spanning finished assays and related reagents or components. This product breadth can support different healthcare and laboratory use cases and provides several avenues for commercial activity over time.
Bears Say
Revenue ContractionRecent revenue performance is volatile and has shifted from a 2024 rebound to two consecutive years of contraction. Sustained top-line weakness can reduce operating leverage, limit reinvestment, and make it harder for the company to absorb fixed costs across its diagnostic business.
Severe Earnings VolatilityThe sharp reversal from strong profitability to a substantial net loss shows that earnings are not yet dependable. Such volatility weakens forecasting confidence, can erode equity value through accumulated losses, and limits the ability to fund growth from internally generated profits.
Recurring Cash BurnNegative operating and free cash flow in 2026, following earlier periods of cash burn, indicates inconsistent cash conversion. Persistent outflows can increase reliance on external funding, restrict investment capacity, and leave less financial resilience if weak trading continues.
Omega Diagnostics News
CNSL FAQ
What was Omega Diagnostics Group PLC’s price range in the past 12 months?
Omega Diagnostics Group PLC lowest share price was 1.25 p and its highest was 2.80 p in the past 12 months.
What is Omega Diagnostics Group PLC’s market cap?
Omega Diagnostics Group PLC’s market cap is £4.05M.
When is Omega Diagnostics Group PLC’s upcoming earnings report date?
Omega Diagnostics Group PLC’s upcoming earnings report date is Nov 19, 2026 which is in 27 days.
How were Omega Diagnostics Group PLC’s earnings last quarter?
Omega Diagnostics Group PLC released its earnings results on Sep 08, 2026. The company reported -0.01 p earnings per share for the quarter, missing the consensus estimate of -0.001 p by -0.009 p.
Is Omega Diagnostics Group PLC overvalued?
According to Wall Street analysts Omega Diagnostics Group PLC’s price is currently Overvalued.
Does Omega Diagnostics Group PLC pay dividends?
Omega Diagnostics Group PLC does not currently pay dividends.
What is Omega Diagnostics Group PLC’s EPS estimate?
Omega Diagnostics Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Omega Diagnostics Group PLC have?
Omega Diagnostics Group PLC has 237,950,650 shares outstanding.
What happened to Omega Diagnostics Group PLC’s price movement after its last earnings report?
Omega Diagnostics Group PLC reported an EPS of -0.01 p in its last earnings report, missing expectations of -0.001 p. Following the earnings report the stock price went down -24.324%.
Which hedge fund is a major shareholder of Omega Diagnostics Group PLC?
Currently, no hedge funds are holding shares in GB:CNSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Omega Diagnostics Group PLC
Established in 1987 and headquartered in London, UK, Cambridge Nutritional Sciences plc (formerly Omega Diagnostics Group PLC until its name change in September 2023) is a specialist in the development, manufacturing, and supply of medical diagnostic products. The company primarily operates within the food sensitivity testing market, creating and producing "Foodprint" branded kits designed to detect immune reactions to food. Beyond manufacturing, it provides clinical analysis services directly to the public, clinics, and healthcare professionals, and also offers the "Food Detective" consumer food test. Its diverse client base includes government entities, private hospitals, reference laboratories, nutritionists, naturopaths, and other medical practitioners. Cambridge Nutritional Sciences plc boasts a global presence, serving markets across the United Kingdom, continental Europe, North, South, and Central America, India, various other Asian countries and the Far East, Africa, and the Middle East.
Technical Analysis
Advanced Medical Solutions
―
EKF Diagnostics Holdings
―
IXICO plc
―
Tristel
―
Abingdon Health PLC
―